Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephalexin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.98 |
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.98 |
| ▸ | HPGD | P15428 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 4/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.83 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.83 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephalexin Anhydrous SCHEMBL5489216 | 1.00 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL5049268 | 1.00 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL27562810 | 1.00 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL40988 | 1.00 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL582342 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL27742537 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL10529259 | 0.99 | HSD17B10 (0.96) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL4928314 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL4928321 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL2961 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| US-3988326-A | Process for N-acylation of 7 amino cephem compounds | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | HSD17B10 3594/4885MAPT 767/4885ALDH1A1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.